Bal Pharma Ltd Share Price

Q: What is the share price of Bal Pharma Ltd today?

Bal Pharma Ltd share price as on 13 Jun 2025 is ₹102.9

Pharmaceuticals

NSE: BALPHARMA Small Cap ISIN: INE083D01012

As on 13 June 2025 at 18:54 IST

₹102.90

-3.66

(-3.43%)

Sell Buy

Over 1 Month

8.28%

Over 6 Months

-12.90%

Over 1 Year

-11.77%

Over 3 Years

11.52%

Bal Pharma Ltd Summary

Close ₹106.56

Open ₹107.20

High ₹111.18

Low ₹105.84

Volume 88,349

Net Turnover (in Cr) ₹0.95

52Wk High ₹157.98

52Wk Low ₹78.06

52Wk High / Low

78.06

157.98

Bal Pharma Ltd Fundamentals

Key Financial Data

Market Cap (in Cr) ₹169.65

EPS (TTM) 4.90

Book Value (BV) 70.67

Div. Yield 1.13 %

P/E (TTM) 21.61

Price/Book Value 1.50

Delivery % 50.54 %

Face Value 10

Key Ratios

PE Ratio 14.04

PB Ratio 1.37

EV to Sales 0.78

PEG Ratio 0.21

ROA 4.18

ROE 10.19

Debt-Equity 1.28

Net Profit Margin 3.03

Operating Profit Margin 10.63

Bal Pharma Ltd Financials

Consolidated

Standalone

Yearly

Quarterly

Profit and Loss

Particulars (in ₹ Cr.)	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Total Revenue	342.07	305.16	286.37	251.67	172.95
Total Expenses	333.02	300.41	277.18	247.56	186.48
Profit Before Tax	9.05	4.75	9.18	4.10	-13.53
Profit After Tax	7.45	2.62	5.70	4.71	-12.89
Operating Profit After Depreciation	24.31	16.93	19.59	16.08	-0.94

Balance Sheet

Particulars (in ₹ Cr.)	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Fixed Assets	76.82	76.46	67.39	68.59	70.71
Total Non Current Assets	85.38	85.02	75.96	75.93	81.02
Total Current Assets	234.15	228.16	184.57	164.15	157.37
Total Assets	319.53	313.17	260.53	240.08	238.39
Total Shareholder's Fund	69.29	63.79	58.63	53.58	52.43

Cash Flow

Particulars (in ₹ Cr.)	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Net Cash From Operating Activities	22.81	-1.54	26.80	22.34	23.24
Net Cash Used In Investing Activities	-18.89	-22.18	-9.48	-5.54	-4.85
Net Cash Used In Financing Activities	-1.21	24.09	-17.22	-16.63	-19.97

Profit and Loss

Particulars (in ₹ Cr.)	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Total Revenue	341.89	305.29	286.86	252	174.30
Total Expenses	329.79	296.74	274.80	242.20	183.38
Profit Before Tax	12.11	8.55	12.06	9.80	-9.08
Profit After Tax	10.27	6.13	8.58	9.10	-8.90
Operating Profit After Depreciation	27.34	21.01	22.45	21.75	3.47

Balance Sheet

Particulars (in ₹ Cr.)	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Fixed Assets	64.56	63.07	52.90	52.65	56.14
Total Non Current Assets	80.16	77.75	71.56	68.34	70.60
Total Current Assets	281.14	269.95	218.20	193.20	168.71
Total Assets	361.30	347.70	289.76	261.54	239.31
Total Shareholder's Fund	105.58	96.03	87.32	79.32	65.94

Cash Flow

Particulars (in ₹ Cr.)	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Net Cash From Operating Activities	28.95	5.38	30.57	10.23	21.71
Net Cash Used In Investing Activities	-18.43	-22.08	-13.43	-6.66	-3.30
Net Cash Used In Financing Activities	-7.71	17.12	-17.22	-3.36	-19.94

Particulars (in ₹ Cr.)	2025-03	2024-12	2024-09	2024-06	2024-03
Total Revenue	81.88	73.15	73.69	74.36	94.63
Total Expenses	74.24	65.39	66	67.89	85.03
Profit Before Tax	2.59	0.57	1.36	0.62	5.75
Profit After Tax	5.42	0.52	1.04	0.26	5.53
Operating Profit after Depreciation	8.72	8.27	7.49	7.29	12.05

Particulars (in ₹ Cr.)	2025-03	2024-12	2024-09	2024-06	2024-03
Total Revenue	81.78	72.89	74.70	73.13	94.58
Total Expenses	73.95	64.95	67.22	66.05	85.40
Profit Before Tax	2.81	0.75	1.53	2.10	5.55
Profit After Tax	5.61	0.69	1.20	1.75	5.34
Operating Profit after Depreciation	8.82	8.45	7.83	7.89	11.03

Bal Pharma Ltd Technicals

Support and Resistance

S3 S2 S1 Pivot R1 R2 R3

S1 104.54

S2 102.52

S3 99.20

Pivot 107.86

R1 109.88

R2 113.20

R3 115.22

Moving Average

20 SMA 99.59

50 SMA 101.38

100 SMA 99.67

200 SMA 113.81

Bal Pharma Ltd Corporate Actions

Bal Pharma Ltd

₹1.2/Share

Announcement Date 17 Sep 2024

Record Date 19 Sep 2024

Div Yield 12%

AGM Date: 19 Sep 2022

AGM 19/09/2022 Register of Members and Share Transfer books of the Company will remain closed from 15th September 2022 to 19th September 2022 ( both days inclusive) to ascertain the entitlement of dividend and for the 35th Annual General Meeting of the Company scheduled to be held on 19.09.2022, i.e on Monday. Sub : Notice of 35th Annual General Meeting and submission of Annual Report for Financial Year 2021-2022 Ref : Regulation 34 of SEBI (LODR) Regulations,2015. As already informed to the exchanges, 35th Annual General Meeting of the Company is scheduled to be held on 19th September 2022 at 11.30 A.M through audio visual means. Notice along with the details of the business to be transacted at the meeting and audited financial statements of the Company for the F.Y ended 30.03.2022 together with the reports of Directors and auditors there on is being dispatched to our shareholders through electronic form. A Copy of the unabridged annual report of the Company for the financial year ended 31.03.2022 is enclosed for submission to the exchanges. Annual report for F.Y 2021.22 is also available on our website i.e www.balpharma.com (As Per BSE Announcement Dated on 26.08.2022) Pursuant to the provisions of Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are submitting to the exchange the business transacted at the 35th Annual General Meeting of the Company conducted through audio visual means, on 19.09.2022. (As Per BSE Announcement Dated on 19.09.2022) We are submitting to the exchange the results of the remote e-voting for 35th Annual General Meeting of the Company held on 19.09.2022, along with the copy of scrutinizers report. The aforesaid reports are also available on our website i.e www.balpharma.com. (As Per BSE Announcement Dated on 21.09.2022)

AGM Date: 25 Sep 2023

AGM 25/09/2023 Board of Directors of the Company has met today and inter alia transacted the following business. 1.Taken on record and approved the Un-audited standalone and consolidated financial results of the Company for the quarter ended 30.06.2023. A copy of the approved financial results together with the limited review report issued by the statutory auditors of the Company with unmodified opinion is enclosed with this intimation. 2. Decided to convene 36th Annual General Meeting of the Company on 25th September 2023 i.e on Monday at 10:30 A.M, through audio visual means. 3. Decided to close the Register of Members and Share transfer books of the Company from 19.09.2023 to 25.09.2023 (both days inclusive) to ascertain the entitlement of Dividend and for the 36th Annual General Meeting of the Company. The meeting commenced at 4.30 p.m. and concluded at 5:40 p.m on Friday, 11th August 2023. (As Per BSE Announcement Dated on 11.08.2023) We are submitting to the exchange the results of the remove e-voting for 36th Annual General Meeting of the Company held on 25.09.2023 with a copy of scrutinizers report. (As Per BSE Announcement Dated on 27/09/2023)

AGM Date: 25 Sep 2024

AGM 25/09/2024 We are submitting to the exchanges the out come of the 37th Annual General Meeting of the Company held on 25.09.2024. (As Per BSE Announcement dated on 25.09.2024) We are submitting the Scrutinizers report on the e-voting done at the 37th Annual General Meeting of the Company held on 25.09.2024. (As per BSE Announcement dated on 26/09/2024)

EGM Date: 14 Dec 2022

EGM 14/12/2022 Extra Ordinary General Meeting of the Company is scheduled to be held on 14th December 2022 at 11.30 a.m, through audio visual means. Notice along with the details of the business to be transacted at the meeting is being dispatched to our shareholders through electronic form. A Copy of the unabridged Notice for the EGM is enclosed for submission to the exchanges. Copy of the EGM notice is also available on our website i.e www.balpharma.com. Board of Directors of the Company has met today and inter alia transacted the following business. 1.Taken on record and approved the Unaudited financial results of the Company for the quarter and half year ended 30.09.2022. A copy of the standalone and consolidated financial results together with the balance sheets, cash flow statements and limited review reports issued by the statutory auditors of the Company with un modified opinion is enclosed . 2.Convened Extra Ordinary meeting of the shareholders of the Company on 14th December 2022 to take their approval for filing application with NCLT for the merger of Golden Drugs Pvt Ltd, a wholly owned subsidiary of the Company. 3.Approved the allotment of 1,17,500 equity shares to the employees of the Company who has exercised the stock options vested on them, under Bal Pharma Ltd employee stock option plan 2014. The Board meeting commenced at 5.30 p.m and concluded at 6.20 p.m on 14.11.2022. (As Per BSE Announcement Dated on 14.11.2022) Pursuant to the provisions of Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are submitting to the exchange the business transacted at the Extra Ordinary General Meeting of the Company conducted through audio visual means, on 14.12.2022. Mr.Shailesh Siroya was elected as Chairman and he chaired the proceedings of the meeting with requisite quorum. Special Business: 1. To seek the consent of the members for filing an application under Section 230(1) of the Companies Act, 2013 with National Company Law Tribunal, Bengaluru Bench in connection with proposed merger of Wholly Owned Subsidiary Company i.e Golden Drugs Private Limited (Transferor Company) with Bal Pharma Limited (Transferee Company). (As per BSE Announcement Dated on 14/12/2022) We are submitting to the exchanges the results of remote e-voting for Extra Ordinary General Meeting of the Company held on 14.11.2022, along with a copy of the Scrutinizers report. (As per BSE Announcement Dated on 16/12/2022)

EGM Date: 03 Oct 2023

We wish to inform that the Company has received order dated 24th August 2023 from Hon''ble National Company Law Tribunal , Bangalore bench ( NCLT) and received by us on 30.08.2023, directing the Company to convene meetings of equity shareholders, Secured and Unsecured creditors of the Company on Tuesday October 3 ,2023 , for the purpose of considering and if thought fit approving the proposed scheme of merger of Golden Drugs Pvt Ltd with Bal Pharma Ltd, its holding Company. The said order of NCLT is enclosed herewith and has also been made available on the Company''s website i.e www.balpharma.com.

EGM Date: 21 Dec 2023

Honorable Bangalore bench of National Company Law Tribunal has convened meetings of shareholders and creditors of Transferer Company i.e Golden Drugs Pvt Ltd and Transferee company i.e Bal Pharma Limited, on 21.12.2023 from 11.00 A.M through audio visual means to inter alia consider approval of scheme of arrangement /merger between transferer Company and Transferee Company. We are submitting to the exchanges newspaper publication of the Notice issued to the Shareholders and Creditors of Bal Pharma Ltd (Transferee Company) and its wholly owned subsidiary Golden Drugs Pvt Ltd (Transferer Company) for the NCLT convened meetings scheduled on 21.12.2023 and published in Financial Express (English) and Vijayavani (Kannada), on 20.11.2023. (As Per BSE Announcement Dated on 21.11.2023) Pursuant to the provisions of Regulation 30 of SEBI (LODR) Regulations ,2015, we are submitting to the exchanges business transacted at the NCLT convened meetings of shareholders, secured and unsecured creditors of the Company, which was conducted through audio visual means on 21.12.2023 (As per BSE Announcement Dated on 21/12/2023) We are submitting to the exchange a copy of the scrutinizers report on the e-voting results of the NCLT convened shareholders meeting of the company held on 21.12.2023. Please take the same on record. (As per BSE Announcement Dated on 22/12/2023)

Bal Pharma Ltd Peer Comparison

Company	Price	Market Cap (in Cr)
Sun Pharmaceutical Industries Ltd	₹1,687	₹4,04,767.81
Divis Laboratories Ltd	₹6,722.75	₹1,78,467.89
Cipla Ltd	₹1,502.10	₹1,21,323.17
Dr Reddys Laboratories Ltd	₹1,363.15	₹1,13,756.67
Torrent Pharmaceuticals Ltd	₹3,260.35	₹1,10,340.10

Bal Pharma Ltd Top Mutal Funds Invested

No data available

Bal Pharma Ltd News

Board of Bal Pharma recommends final dividend

Of Rs 1.2 per share

30 May 2025, 11:20 am

Bal Pharma to declare Quarterly Results

On 29 May 2025

17 May 2025, 11:42 am

Bal Pharma Ltd leads gainers in 'B' group

Chemcrux Enterprises Ltd, Maral Overseas Ltd, Growington Ventures India Ltd and Orchasp Ltd are among the other gainers in the BSE's 'B' group today, 03 April 2025.

03 Apr 2025, 12:15 pm

Bal Pharma to hold board meeting

On 13 February 2025

25 Jan 2025, 10:17 am

Bal Pharma schedules board meeting

On 14 November 2024

06 Nov 2024, 08:13 pm

Bal Pharma Ltd Stock Analysis

Annual revenue for Bal Pharma Ltd increased by 11.99% to ₹341.89 crore in FY 2024 from ₹305.29 crore in FY 2023.
Annual Net Profit for Bal Pharma Ltd increased by 67.68% to ₹10.27 crore in FY 2024 from ₹6.13 crore in FY 2023.
Promoter Shareholding in Bal Pharma Ltd remains unchanged by 0.00% in the most recent quarter, from 50.86% in December 2024 to 50.86% in March 2025.
Bal Pharma Ltd delivered a 1-year return of -11.77% compared to the Nifty 50, which provided a return of 6.71% as of the last trading session.
Bal Pharma Ltd share price moved down by 3.43% from its previous close of INR ₹106.56. The latest Bal Pharma Ltd share price is INR ₹102.90.
Bal Pharma Ltd share price today has been at a low of 101.05 and a high of 104.95. Over the past 52 weeks, the Bal Pharma Ltd share price has seen a low of 78.06 and a high of 157.98.